

Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons

Nady Braidy · Ross Grant · Seray Adams ·
Bruce J. Brew · Gilles J. Guillemain

Received: 12 December 2008 / Revised: 31 March 2009 / Accepted: 2 April 2009 / Published online: 18 April 2009
© Springer Science+Business Media, LLC 2009

Abstract There is growing evidence implicating the kynurenine pathway (KP) and particularly one of its metabolites, quinolinic acid (QUIN), as important contributors to neuroinflammation in several brain diseases. While QUIN has been shown to induce neuronal and astrocytic apoptosis, the exact mechanisms leading to cell death remain unclear. To determine the mechanism of QUIN-mediated excitotoxicity in human brain cells, we measured intracellular levels of nicotinamide adenine dinucleotide (NAD^+) and poly(ADP-ribose) polymerase (PARP) and extracellular lactate dehydrogenase (LDH) activities in primary cultures of human neurons and astrocytes treated with QUIN. We found that QUIN acts as a substrate for NAD^+ synthesis at very low concentrations (<50 nM) in both neurons and astrocytes, but is cytotoxic at sub-physiological concentrations (>150 nM) in both the cell types. We have shown that the NMDA ion channel blockers, MK801 and memantine, and the nitric oxide synthase (NOS) inhibitor, L-NAME, significantly attenuate QUIN-mediated PARP activation, NAD^+ depletion, and

LDH release in both neurons and astrocytes. An increased mRNA and protein expression of the inducible (iNOS) and neuronal (nNOS) forms of nitric oxide synthase was also observed following exposure of both cell types to QUIN. Taken together these results suggests that QUIN-induced cytotoxic effects on neurons and astrocytes are likely to be mediated by an over activation of an NMDA-like receptor with subsequent induction of NOS and excessive nitric oxide (NO^*)-mediated free radical damage. These results contribute significantly to our understanding of the pathophysiological mechanisms involved in QUIN neuro- and gliotoxicity and are relevant for the development of therapies for neuroinflammatory diseases.

Keywords Nitric oxide · Quinolinic acid · Astrocytes · Neurons · Alzheimer's disease · Neurodegeneration

Introduction

The kynurenine pathway (KP) is the main route of L-tryptophan catabolism resulting in the production of the essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD^+) (Stone 1993). The KP also leads to the production of several neuroreactive metabolites, of which the NMDA receptor agonist, quinolinic acid (QUIN) is likely to be more important in terms of biological activity. (Heyes 1993; Stone 2001). QUIN is known to be associated with the neuropathogenesis of Alzheimer's disease (Guillemain and Brew 2002), Huntington's disease (Finkbeiner and Cuero 2006), amyotrophic lateral sclerosis (Guillemain et al. 2005a), and human immunodeficiency virus (Guillemain et al. 2005b; Heyes et al. 1991; Heyes et al. 1992). QUIN levels in the central nervous system also increase with age (Moroni et al. 1984).

N. Braidy · R. Grant · S. Adams · G. J. Guillemain (✉)
Department of Pharmacology, Faculty of Medicine, University
of New South Wales, Sydney 2052, Australia
e-mail: g.guillemain@cfi.unsw.edu.au

R. Grant
Australasian Research Institute, Sydney Adventist Hospital,
Sydney, Australia

B. J. Brew · G. J. Guillemain
St Vincent's Centre for Applied Medical Research,
Sydney, Australia

B. J. Brew
Department of Neurology, St Vincent's Hospital,
Sydney, Australia

QUIN is known to promote oligodendrocyte, neuronal, and astrocytic apoptosis at pathophysiological concentrations (Cammer 2002; Guillemín et al. 2005c; Kelly and Burke 1996). Although the mechanism has not been completely elucidated, it appears to be involved for a large part the formation of reactive oxygen species (ROS) possibly mediated via the NMDA receptor (Behan et al. 1999; Guillemín and Brew 2002; Kerr et al. 1998). Activation of NMDA receptors by agonists such as glutamate and QUIN opens a channel permeable to Na^+ and Ca^{2+} ions (Guillemín et al. 2005b; Stone and Perkins 1981). An increase in intracellular Ca^{2+} has been shown to trigger numerous destructive processes, including increased nitric oxide synthase (NOS) activity, which can promote increased nitric oxide (NO^\bullet) and free-radical damage, leading to mitochondrial dysfunction and DNA strand breaks (Atlante et al. 1997; Behan et al. 1999; Velazquez et al. 1997). QUIN leads to the generation of ROS having been shown to induce lipid peroxidation in the rat brain (Behan et al. 1999; Santamaria et al. 2001).

NOS is a family of enzymes including the inducible isoform (iNOS) and the constitutive forms: neuronal (nNOS) and endothelial (eNOS). It has been previously shown that iNOS transcription is induced during inflammation in response to cytokine stimulation (Possel et al. 2000) and several endotoxins, including QUIN (Rya et al. 2004). Activation of nNOS also has several implications in neuroinflammation: (1) NMDA receptor-mediated excitotoxicity is reduced in response to NOS inhibition in cultured rat cortical neurons (Dawson et al. 1991); (2) nNOS knockout mice report a significant reduction in death due to NMDA receptor-mediated excitotoxicity (Ayata et al. 1997); (3) nNOS activity is increased following QUIN injection in the rat striatum (Aguilera et al. 2007; Perez-Severiano et al. 1998).

Oxidative DNA damage is known to stimulate the activity of the NAD^+ dependent nuclear DNA repair enzyme, poly(ADP-ribose) polymerase (PARP-1) (EC 2.4.2.31). PARP activation leads to DNA repair and recovery of normal cellular function. However, excessive activation of PARP by DNA strand breaks induced by ROS results in the depletion of intracellular NAD^+ and ATP stores culminating in cell death due to reduced energy metabolism (Braidy et al. 2008; Ha and Snyder 1999; Zhang et al. 1994).

While QUIN-mediated activation of the NMDA receptor is a well known cause of apoptosis in the neuron (Kelly and Burke 1996; Kerr et al. 1995; Stone 2001), the role of the NMDA receptor and iNOS activation in QUIN-mediated cell death in the astrocyte has not been reported.

Considering the important relationship between ROS, PARP activity, and NAD^+ levels, we measured the effect of QUIN at pathophysiological concentrations on

intracellular NAD^+ levels and PARP activity in primary cultures of human astrocytes and neurons. Extracellular lactate dehydrogenase (LDH) activity was used to quantify cytotoxicity. We also tested whether NMDA receptor antagonism and NOS inhibition could protect human astrocytes from QUIN excitotoxicity. We used RT-PCR to quantify iNOS and nNOS mRNA expression in purified primary cultures of human fetal astrocytes and neurons following QUIN treatment. Immunocytochemistry was also used to detect iNOS and nNOS protein expression.

In this study we show that, paradoxically, QUIN at very low concentrations can have a cytoprotective role as a precursor for NAD^+ synthesis. However, at subphysiological concentrations it quickly becomes cytotoxic to both neurons and astrocytes. Our data suggest that the mechanism for QUIN toxicity is similar in both human astrocytes and neurons involving NMDA receptor activation and NO^\bullet production. Understanding the mechanism through which QUIN produces its cytotoxic effect in human brain cells is therefore of potential therapeutic importance.

Materials and Methods

Reagents and Chemicals

Dulbecco's phosphate buffer solution (DBPS) and all other cell culture media and supplements were from Invitrogen (Melbourne, Australia) unless otherwise stated. Nicotinamide, bicine, β -nicotinamide adenine dinucleotide reduced form (β -NADH), 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), alcohol dehydrogenase (ADH), sodium pyruvate, TRIS, γ -globulins, quinolinic acid (QUIN), (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801), memantine, D-2-amino-5-phosphonovalerate (AP-5), and N(G)-nitro-L-arginine methylester (L-NAME), mouse mAb anti-iNOS and anti-nNOS, DAPI, and pAb anti-GFAP were obtained from Sigma-Aldrich (Castle-Hill, Australia). Phenazine methosulfate (PMS) was obtained from ICN Biochemicals (Ohio, USA). Bradford reagent was obtained from BioRad, Hercules (CA, USA). Mouse anti-MAP2 were obtained from Millipore (Melbourne, Australia). Secondary anti-mouse IgG and anti-rabbit Alexa 488 (green) or Alexa 594 (red)-conjugated antibodies were purchased from Molecular Probes (Eugene, OR). All commercial antibodies were used at the concentrations specified by the manufacturers.

Cell Cultures

Human fetal brains were obtained from 16 to 19-week-old fetuses collected following therapeutic termination with

informed consent. Mixed brain cultures were prepared and maintained using a protocol previously described by Guillemain et al. (2005c).

Astrocytes were prepared from the mixed brain cell cultures using a protocol previously described by Guillemain et al. (2001). Cells were cultured in medium RPMI 1640 supplemented with 10% fetal bovine serum, 1% l-glutamax, 1% antibacterial/antifungal, and 0.5% glucose. Cells were maintained at 37°C in a humidified atmosphere containing 95% air/5% CO₂. Cells were seeded into 24-well tissue culture plates to a density of 1×10^5 cells 24 h prior to experimentation.

Neurons were prepared from the same mixed brain cell cultures as previously described (Guillemain et al. 2007). Briefly, cells were plated in 24-well culture plates coated with Matrigel (1/20 in Neurobasal) and maintained in Neurobasal medium supplemented with 1% B-27 supplement, 1% Glutamax, 1% antibiotic/antifungal, 0.5% HEPES buffer, and 0.5% glucose.

Primary Brain Cells and QUIN Culture Treatments

Human astrocytes and neurons were treated with 50–1200 nM QUIN. Cell homogenates, culture supernatants, and RNA were collected after 24 h. Experiments were performed in quadruplicates using cultures derived from three different human fetal brains.

NAD(H) Microcycling Assay for the Measurement of Intracellular NAD⁺ Concentrations

Intracellular NAD⁺ concentration was measured spectrophotometrically using the thiazolyl blue microcycling assay established by Bernofsky and Swan (1973) adapted for 96-well plate format by Grant and Kapoor (1998).

Extracellular LDH Activity as a Measurement for Cytotoxicity

The release of lactate dehydrogenase (LDH) into culture supernatant correlates with the amount of cell death and membrane damage, providing an accurate measure of cellular toxicity. LDH activity was assayed using a standard spectrophotometric technique described by Koh and Choi (1987).

PARP Assay for the Measurement of Intracellular PARP Activity

PARP activity was measured using a new operational protocol relying on the chemical quantification of NAD⁺ modified from Putt et al (2005). Briefly, plated cells are washed twice with DPBS and another 500 µl was added

per well. Cells were then treated with known concentrations of QUIN and incubated for 15 min. DPBS solution was then aspirated and PARP lysing buffer (200 µl) was added to the cell plate. The buffer solution contained MgCl₂ (10 mM), Triton X-100 (1%), and NAD⁺ (20 µM) in Tris buffer (50 mM, pH 8.1). The plate was then incubated for 1 h and the amount of NAD⁺ consumed was measured by the NAD(H) microcycling assay using the Model 680XR microplate reader (BioRad, Hercules).

Bradford Protein Assay for the Quantification of Total Protein

NAD⁺ concentration, PARP, and extracellular LDH activities were adjusted for variations in cell number using the Bradford protein assay described by Bradford (1976).

RT-PCR of iNOS, nNOS, and GAPDH mRNA Expression

The method for RT-PCR has been previously described (Guillemain et al. 2001). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene. The primer sequences are as follows (1) iNOS forward primer: TCCGCTATGCTGGCTACCA; reverse primer CACTCGTATTTGGGATGTTCCA. (2) nNOS forward primer: CAGCACGGCATCTGCTTTG; reverse primer CATCCCACGTCCATTCTTTT. (3) GAPDH forward primer: CTGAGTGTAGCCAGGATGC; reverse primer ACCACCATGGAGAAGGCTGG. The intensity of the signal was quantified using the application Adobe Photoshop (Adobe Systems Incorporated, USA).

Immunocytochemistry for the Detection of iNOS and nNOS Expression

The method for immunocytochemistry has been previously described (Guillemain et al. 2007). Cells were incubated with selected primary antibodies mAb iNOS and mAb nNOS, together with phenotypic markers (GFAP, MAP-2). Selected secondary antibodies (goat anti-mouse IgG or goat anti-rabbit coupled with Alexa 488 or Alexa 594) were used. The following controls were performed for each labelled experiment: (1) isotypic antibody controls and (2) incubation with only the secondary labelled antibody.

Data Analysis

Results obtained are presented as the means \pm the standard error of measurement (SEM). One way analysis of variance (ANOVA) and post hoc Tukey's multiple comparison tests were used to determine statistical significance between treatment groups. Differences between treatment groups

were considered significant if P was less than 0.05 ($P < 0.05$).

Results

Effect of QUIN on Intracellular NAD^+ Concentrations and Extracellular LDH Activity in Human Astrocytes and Neurons

While QUIN is known to be excitotoxic to neurons, we chose to investigate recent evidence that QUIN may also be cytotoxic to astrocytes. Astrocytes and neurons were treated with QUIN for 24 h at increasing concentrations (50, 150, 350, 550, and 1200 nM), respectively. NAD^+ depletion was observed in a dose-dependent manner at concentrations above 150 nM (Fig. 1a and b). However, the intracellular NAD^+ concentration in astrocytes and neurons treated with 50 nM of QUIN was significantly greater when compared to non-treated astrocytes (Fig. 1a) and neurons (Fig. 1b). As expected the decrease in cellular NAD^+ levels correlated negatively with increasing extracellular LDH activity in a dose-dependent manner at QUIN concentrations greater than 150 nM in human astrocytes (Fig. 2a) and neurons (Fig. 2b) over 24 h.

Effect of NMDA Receptor Antagonism and nNOS Inhibition on QUIN-Mediated NAD^+ Depletion, Extracellular LDH, and PARP Activities in Human Neurons

To determine if NMDA receptor activation and subsequent nitric oxide (NO^*) production are involved in QUIN toxicity in primary human neurons, we monitored the effect of NMDA receptor antagonism and nNOS inhibition on intracellular NAD^+ levels, PARP, and extracellular LDH activities. The NMDA ion channel blocker, MK-801 (1 μM) and NOS inhibitor, L-NAME (100 μM) were able to prevent NAD^+ depletion in human neurons in 24 h (Fig. 3a). Significant activation of PARP was observed in neurons treated with QUIN (550 nM) for 24 h (Fig. 3b). Treatment with MK-801 (1 μM) and L-NAME (100 μM) were able to significantly reduce PARP activation and subsequent NAD^+ depletion in human neurons in 24 h (Fig. 3b). Extracellular LDH activity was significantly reduced following treatment with MK-801 (1 μM) and L-NAME (100 μM) in the presence of QUIN (550 nM) (Fig. 3c), corresponding to the observed preservation of intracellular NAD^+ levels (Fig. 3a) and reduced PARP activity (Fig. 3b).

Fig. 1 QUIN treatment (0–1200 nM) on intracellular NAD^+ in **a** human astrocytes and **b** human neurons for 24 h. Significance * $P < 0.05$, ** $P < 0.01$ compared to previous dose ($n = 4$ for each treatment group)




Fig. 2 QUIN treatment (0–1200 nM) on extracellular LDH activity in **a** human astrocytes and **b** human neurons for 24 h. Significance * $P < 0.05$, ** $P < 0.01$ compared to previous dose ($n = 4$ for each treatment group)





Fig. 3 Effect of NMDA receptor antagonism and nNOS inhibition on QUIN-induced changes in **a** intracellular NAD⁺ levels, **b** PARP activity, and **c** extracellular LDH activity in human neurons. **a** **P* < 0.05 compared to control (*n* = 4 for each treatment group). **b** **P* < 0.05 compared to control (*n* = 4 for each treatment group). **c** **P* < 0.05 compared to control (*n* = 4 for each treatment group)



Effect of NMDA Receptor Antagonism and iNOS Inhibition on QUIN-Mediated NAD⁺ Depletion, Extracellular LDH, and PARP Activities in Human Astrocytes


We assessed whether a similar mechanism is involved in QUIN toxicity on primary human astrocytes. Addition of MK-801 (0.1–2 μM) attenuated QUIN-mediated NAD⁺ depletion after 24 h (Fig. 4a). However, higher doses (>10 μM) generated a significant decrease in NAD⁺ compared to lower doses. Memantine, a lower affinity NMDA ion channel blocker also prevented NAD⁺ depletion at higher concentrations (2–10 μM). AP-5, a competitive NMDA receptor antagonist at the glutamate site showed no significant effect on NAD⁺ up to 10 μM; however, intracellular NAD⁺ depletion was slightly ameliorated at 50 μM of treatment (Fig. 4a).

Astrocytes treated with QUIN at 550 nM for 1 h showed significantly increased PARP activity compared to the control (Fig. 4b), consistent with the previous results

showing QUIN can affect NAD⁺ concentration (Fig. 4a). Concomitant treatment of these cells with MK-801 (0.1–2 μM) significantly reduced PARP activity compared to QUIN treatment alone. Treatment with memantine (0.5–10 μM) and AP-5 (10–50 μM) also reduced PARP activity, but to a lesser extent than MK-801 (Fig. 4b).

To investigate whether QUIN toxicity was mediated via NMDA-induced NO[•] production, astrocytes were treated with the iNOS inhibitor L-NAME at a final concentration of 100 μM. L-NAME treatment prevented QUIN-mediated NAD⁺ depletion at the cytotoxic QUIN concentrations of 550 and 1200 nM (Fig. 5a). Consistent with results for NAD⁺ depletion (Fig. 5a), astrocytes treated with QUIN (550 and 1200 nM) in the presence of L-NAME (100 μM), had significantly lower PARP activity (Fig. 5b). Again, consistent with results already presented for NAD⁺ (Fig. 5a) and PARP (Fig. 5b), cells treated with QUIN (550 and 1200 nM) in the presence of L-NAME (100 μM) showed significantly reduced extracellular LDH activity in culture supernatants after 24 h (Fig. 5c).

Fig. 4 Effect of NMDA receptor antagonism on QUIN-induced changes in **a** intracellular NAD⁺ levels, **b** PARP activity in human astrocytes. **a** MK-801, memantine, and AP-5 (0–50 μ M) on QUIN-induced NAD⁺ depletion in human astrocytes for 24 h. * P < 0.05 compared to control; $\forall P$ < 0.05 compared to QUIN treatment alone. (n = 4 for each treatment group). **b** MK-801, memantine, and AP-5 (0–50 μ M) on QUIN-induced PARP activation in human astrocytes for 24 h. * P < 0.05 compared to control; $\forall P$ < 0.05 compared to QUIN treatment alone. (n = 4 for each treatment group)



Detection of iNOS and nNOS mRNA Expression in Human Astrocytes and Neurons

Expression of the mRNA for human iNOS was studied in primary cultures of human astrocytes (Fig. 6a) and neurons (Fig. 6b) with and without QUIN (550 nM) exposure for 24 h. As previously described, iNOS was not expressed in human neurons (Aguilera et al. 2007). Based on the ratio of iNOS and nNOS expression relative to GAPDH expression, iNOS and nNOS expression was significantly higher in QUIN-treated astrocytes (Fig. 6c) and neurons (Fig. 6d), respectively, compared to non-treated cells.

Detection of iNOS and nNOS Expression in Human Astrocytes and Neurons

Immunocytochemical studies were performed to demonstrate that increased iNOS and nNOS expression was not limited to mRNA alone and reflects increased protein production. Higher immunoreactivity for iNOS and nNOS enzyme proteins was detected in human fetal astrocytes and neurons in the presences of QUIN (550 nM) compared to untreated cultures and cells co-treated with MK-801 (100 μ M) and L-NAME (100 μ M) for 24 h (Fig. 7). Double staining with MAP-2 and GFAP demonstrated that iNOS and nNOS were specifically expressed by astrocytes and neurons, respectively.


Discussion

In this study, we assessed the effects of pathophysiological concentrations of QUIN on intracellular NAD⁺ and extracellular LDH activity in human astrocytes and neurons. A dose-dependent decrease in intracellular NAD⁺ (Fig. 1) and a corresponding increase in extracellular LDH activity (Fig. 2) were observed in both brain cell types for concentrations above 150 nM. Our in vitro results for QUIN toxicity are in accordance with previous studies using brain cell cultures (Ting et al. 2007; Guillemain et al. 2005d; Kerr et al. 1998) and animal models (Bjorklund et al. 1984; Dihne et al. 2001).

Interestingly, a significant increase in intracellular NAD⁺ was observed in human astrocytes and neurons treated with 50 nM of QUIN (physiological concentration). This indicates that extracellular QUIN can be taken up as a substrate for NAD⁺ synthesis. This is supported by the previous study from Grant and Kapoor (1998) who showed that QUIN could contribute significantly to NAD⁺ regeneration following acute H₂O₂-induced depletion in primary glial cells.

QUIN-induced cytotoxicity in neurons has long been known to involve over-activation of the NMDA receptor (Stone 2001). NMDA receptor activation and subsequent influx of Ca²⁺ into neurons activate nNOS and downstream enzymes, leading to the production of NO[•] and other free

Fig. 5 Effect of iNOS inhibition on QUIN-induced changes in **a** intracellular NAD⁺ levels, **b** PARP activity, and **c** extracellular LDH activity in human astrocytes. **a** L-NAME (100 μM) on QUIN-induced NAD⁺ depletion in human astrocytes for 24 h. **P* < 0.05 compared to control (*n* = 4 for each treatment group). **b** L-NAME (100 μM) on QUIN-induced PARP activation in human astrocytes for 24 h. **P* < 0.05 compared to control (*n* = 4 for each treatment group). **c** L-NAME (100 μM) on QUIN-induced extracellular LDH activity in human astrocytes for 24 h. **P* < 0.05 compared to control (*n* = 4 for each treatment group)




radicals able to cause DNA strand breaks and pathological activation of PARP, NAD⁺ depletion, and cell death due to energy deprivation (Ha and Snyder 1999; Zhang et al. 1994). In this study, we have shown that QUIN at concentrations ≥150 nM significantly increased PARP activity (Fig. 3b) resulting in NAD depletion (Fig. 3a) and cell death, indicated by a corresponding increase in LDH activity (Fig. 3c). These results are consistent with previous work by Maldonado et al (2007), who showed that PARP activation and subsequent NAD⁺ depletion plays an active role in neuronal cell death induced by QUIN in the rat brain.

In addition, we showed that the NMDA ion channel blocker, MK-801, and the NOS inhibitor, L-NAME, can prevent QUIN-induced neurotoxicity by reducing NAD⁺ depletion (Fig. 3a) and PARP activation (Fig. 3b). These

results are again consistent with previous studies which have shown that NMDA receptor antagonism and NOS inhibition prevent QUIN-induced toxicity in rat neurons (Stone 2001).

Although mechanisms involved in QUIN cytotoxicity on neurons are well established (Guillemin et al. 2005a, b, c, d), the biochemical pathway leading to QUIN-induced cell death in astrocytes is largely unknown. In this study we showed that QUIN cytotoxicity on astrocytes is mediated by a similar pathway as in neurons involving iNOS induction through activation of a glial NMDA-like receptor. While it is understood that the existence of functional NMDA receptors in human astrocytes is currently controversial (Conti et al. 1996; Guillemin et al. 2005b), recent work by our group has demonstrated the presence of

Fig. 6 Expression of iNOS, nNOS, and GAPDH mRNA in purified primary human fetal astrocytes and neurons after QUIN (550 nM) stimulation. Photograph of ethidium bromide-stained gel showing RT-PCR for iNOS (amplicon size: 220 pb), nNOS (amplicon size 210 pb), and GAPDH (amplicon size: 509 pb) in **a** astrocytes **b** neurons. Histogram showing the ratio of iNOS and nNOS expression relative to the GAPDH expression in **c** astrocytes, **d** neurons. * $P < 0.05$ compared to control. Standard errors were $\leq 10\%$



functional NMDA receptors in primary human astrocytes (data not shown).


We observed that synthetic NMDA receptor antagonists, MK-801 and memantine, were able to successfully improve QUIN-mediated NAD^+ depletion and cell death. The NMDA channel blocker MK-801 and memantine dose dependently prevented QUIN-induced cell death in astrocytes (Fig. 4a) with MK-801 having a stronger effect than memantine at lower concentrations ranging from 0.1 to 2 μM , but not at higher concentrations (10–50 μM) (Fig. 4a). AP-5, an antagonist at the glutamate site of the NMDA receptor showed only a partial protective effect on NAD^+ at very high concentrations (50 μM) (Fig. 4a). This pattern of protection in astrocytes is consistent with a previous study using mouse neurons that showed that MK-801 and memantine were more successful at reducing QUIN toxicity than AP-5 because of their non-competitive action on the NMDA receptor (Wong et al. 1986).

Human primary astrocytes showed a significant increase in PARP activity when exposed to ≥ 150 nM QUIN. Treatment with MK-801 or memantine, and to a lesser extent AP-5, reduced PARP activation in a dose dependent manner (Fig. 4b). The involvement of NO^\bullet in the death of astrocytes was evident when treatment with the NOS inhibitor; L-NAME essentially blocked QUIN-induced NAD^+ depletion (Fig. 5a), PARP activation (Fig. 5b) and extracellular LDH activity (Fig. 5c). We also observed that exposure of astrocytes to QUIN for 24 h dramatically

increased iNOS mRNA expression (Fig. 6a, c). Although iNOS mRNA (Fig. 6b) was not expressed in human neurons (Aguilera et al. 2007) nNOS mRNA expression was significantly increased in QUIN-treated neurons compared to non-treated cells (Fig. 6b, d). This is further supported through increased iNOS and nNOS protein expression in QUIN-treated human astrocytes and neurons compared to non-treated cells and cells treated with NMDA receptor antagonists or a NOS inhibitor (Fig. 7).

Together, these results indicate that activation of a glial NMDA-like receptor followed by excess NO^\bullet production, DNA damage, PARP activation, and subsequent NAD^+ depletion is a primary mechanism for QUIN-associated toxicity in human astrocytes similar to that found in our study and previously reported for neurons. Moreover, these studies suggest that nervous tissue NO^\bullet , not only serves as an essential neuronal messenger, but may also play a major role in QUIN toxicity. Previous studies have shown that PARP inhibition can prevent the depletion of intracellular NAD^+ and ATP stores, and therefore prevent cell death (Ha and Snyder 1999; Zhang et al. 1994). In addition, replenishing intracellular NAD^+ can prevent PARP-1-mediated astrocyte death in rat cultures as reported by Du et al (2003) using liposomal NAD^+ delivery into rat neurons. Identification of pathways through which QUIN promotes astrocytic and neuronal death may increase our understanding of several inflammatory brain diseases, and thus pave the way for effective and innovative therapeutic approaches.

Fig. 7 Immunocytochemical detection of iNOS and nNOS in purified primary human fetal astrocytes and neurons after QUIN (550 nM) stimulation. **a** Staining for iNOS in human astrocytes: top, double staining for iNOS/green and DAPI/blue; center, double staining for GFAP/red and DAPI/blue; bottom, merged iNOS/green, GFAP/red, and DAPI/blue. **b** Staining for nNOS in human neurons: top, double staining for nNOS/green and DAPI/blue; center, double staining for MAP-2/red and DAPI/blue; bottom, merged nNOS/green, MAP-2/red, and DAPI/blue



References

- Aguilera P, Chanez-Cardenas ME, Floriano-Snachez E, Barrera D, Santamaria A, Sanchez-Gonzalez DJ, Perez-Severiano F, Pedraza-Chaverri J, Jimenez PDM (2007) Time related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. *Neurotoxicology* 28:1200–1207
- Atlante A, Gagliardi S, Minervini GM, Ciotti MT, Marra E, Calissano P (1997) Glutamate neurotoxicity in rat cerebellar granule cells: a major role of xanthine oxidase in oxygen radical formation. *J Neurochem* 68:2038–2045
- Ayata C, Ayata G, Hara H, Mathews RT, Beal MF, Ferrante RJ (1997) Mechanisms of reduced striatal NMDA excitotoxicity in type 1 nitric oxide synthase knock-out mice. *J Neurosci* 17:6908–6917
- Behan WM, McDonald M, Darlington LG, Stone TW (1999) Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. *Br J Pharmacol* 128(8):1754–1760
- Bernofsky C, Swan M (1973) An improved cycling assay for nicotinamide adenine dinucleotide. *Anal Biochem* 53:452–458
- Bjorklund H, Eriksdotter-Nilsson M, Dahl D, Olson L (1984) Astrocytes in smears of CNS tissues as visualized by GFA and vimentin immunofluorescence. *Med Biol* 62(1):38–48
- Bradford MM (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilising the principle of protein-dye binding. *Anal Biochem* 53:452–458
- Braidy N, Guillemin G, Grant R (2008) Promotion of cellular NAD⁺ anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. *Neurotox Res* 13(3, 4):173–184
- Cammer W (2002) Apoptosis of oligodendrocytes in secondary cultures from neonatal rat brains. *Neurosci Lett* 327(2):123–127
- Conti F, DeBiasi S, Minelli A, Melone M (1996) Expression of NR1 and NR2A/B subunits of the NMDA receptor in cortical astrocytes. *Glia* 17(3):254–258

- Dawson VL, Dawson TM, London ED, Brecht DS, Snyder SH (1991) Nitric oxide synthase mediates glutamate neurotoxicity in primary cortical cultures. *Proc Natl Acad Sci USA* 88:6368–6637
- Dihne M, Block F, Korr H, Topper R (2001) Time course of glial proliferation and glial apoptosis following excitotoxic CNS injury. *Brain Res* 902(2):178–189
- Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, Grraham SH, Carcillo JA, Szabo C, Clark RS (2003) Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD⁺ depletion and cell death induced by oxidative stress. *J Biol Chem* 278:18426–18433
- Finkbeiner S, Cuero AM (2006) Disease modifying pathways in neurodegeneration. *J Neurosci* 26:10349–10357
- Grant RS, Kapoor V (1998) Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. *J Neurochem* 70:1759–1763
- Guillemin GJ, Brew BJ (2002) Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. *Redox Rep* 7(4):199–206
- Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. *J Neurochem* 78:1–13
- Guillemin GJ, Meninger V, Brew BJ (2005a) Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. *Neurodegener Dis* 2(3–4):166–176
- Guillemin GJ, Kerr SJ, Brew BJ (2005b) Involvement of quinolinic acid in AIDS dementia complex. *Neurotox Res* 7(1–2):103–123
- Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005c) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. *Glia* 49(1):15–23
- Guillemin GJ, Wang L, Brew BJ (2005d) Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. *J Neuroinflammation* 2(16):1–6
- Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, Takikawa O, Brew BJ (2007) Characterization of the kynurenine pathway in human neurons. *J Neurosci* 27(47):12884–12892
- Ha HC, Snyder SH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. *Proc Natl Acad Sci USA* 96:13978–13982
- Heyes MP (1993) Quinolinic acid and inflammation. *Ann N Y Acad Sci* 679:211–216
- Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, Yergy JA, Mouradian MM, Sadler AE, Keilp J et al (1991) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. *Ann Neurol* 29(2):202–209
- Heyes MP, Jordan EK, Lee K, Saito K, Frank JA, Snoy PJ, Markey SP, Gravell M (1992) Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. *Brain Res* 570(1–2):237–250
- Kelly WJ, Burke RE (1996) Apoptotic neuron death in rat substantia nigra induced by striatal excitotoxic injury is developmentally dependent. *Neurosci Lett* 220(2):85–88
- Kerr SJ, Armati PJ, Brew BJ (1995) Neurocytotoxicity of quinolinic acid in human brain cultures. *J Neurovirol* 1(5–6):375–380
- Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ (1998) Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. *AIDS* 12(4):355–363
- Koh JY, Choi DW (1987) Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. *J Neurosci Methods* 20:83–90
- Maldonado PD, Chanez-Cardenas ME, Barrera D, Villeda-Hernandez J, Santamaria A, Pedraza-Chaverri J (2007) Poly(ADP-ribose) polymerase-1 is involved in the neuronal death induced by quinolinic acid in rats. *Neurosci Lett* 425:28–33
- Moroni F, Lombardi G, Moneti G, Aldinio C (1984) The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during the aging process. *Neurosci Lett* 47(1):51–55
- Perez-Severiano F, Escalante B, Rios C (1998) Nitric oxide synthase inhibition prevents acute quinolinate-induced striatal neurotoxicity. *Neurochem Res* 23:1297–1302
- Possel H, Noack H, Putzke J, Wolf G, Seis H (2000) Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. *Glia* 32:51–59
- Putt KS, Beilman GJ, Hergenrother PJ (2005) Direct quantification of poly(ADP-ribose) polymerase (PARP) activity as a means to distinguish necrotic and apoptotic death in cell and tissue samples. *Chembiochem* 6:53–55
- Rya JK, Kim SU, McLarnon JG (2004) Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. *Exp Neurol* 187:150–159
- Santamaria A, Jimenez-Capdeville ME, Camacho A, Rodriguez-Martinez E, Flores A, Galvan-Arzate S (2001) In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. *Neuroreport* 12(12):2693–2696
- Stone TW (1993) Neuropharmacology of quinolinic and kynurenic acids. *Pharmacol Rev* 45(3):309–379
- Stone TW (2001) Endogenous neurotoxins from tryptophan. *Toxicol* 39(1):61–73
- Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. *Eur J Pharmacol* 72(4):411–412
- Ting KK, Brew B, Guillemin G (2007) The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. *Neurotox Res* 12(4):247–262
- Velazquez JLP, Frantseva MV, Carlen PL (1997) In-vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons. *J Neurosci* 17:9085–9094
- Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. *Proc Natl Acad Sci USA* 83:7104–7108
- Zhang J, Dawson VL, Dawson TM, Snyder SH (1994) Nitric oxide activation of poly (ADP-ribose) synthetase in neurotoxicity. *Science* 263(5147):687–689